Navigation Links
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes
Date:6/18/2013

LAVAL, Quebec, June 18, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (the "Company") announced today that VPII Escrow Corp., a newly formed wholly owned Canadian subsidiary of the Company, has launched its offer of approximately $3.2 billion aggregate principal amount of senior unsecured notes (the "Notes").  The Notes will be due in 2021 and in 2023, with final tranching determined at pricing.

The Company intends to use the net proceeds from the offering, together with proceeds from its previously announced public offering of common shares and other debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This press release shall not constitute
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals Prices Public Offering Of Common Shares
2. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
3. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
4. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
5. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
6. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
7. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
8. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
9. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
10. Valeant Pharmaceuticals Provides Efinconazole Update
11. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Tianyin Pharmaceutical Co., Inc., (NYSE Amex: ... and markets patented biopharmaceutical, modernized traditional Chinese medicine, ... the senior management will host a conference call ... financial results at 8:30 a.m. E.T. on Tuesday, ...
... LEIPZIG, Germany, Feb. 8, 2011 Data from the ... the SUPERA® stent for peripheral arterial disease (PAD) of ... Leipzig Interventional Course (LINC).  The SUPERA stent is CE ...  In the United States the SUPERA stent is the ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 3
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Symphony Platelet Concentrate System is a ... of Platelet Concentrate (also referred to as ... Poor Plasma (PPP) from a small sample ... body's natural growth factors, which are found ...
Medicine Products: